プラダー･ウィリ症候群(Prader-Willi Syndrome (PWS))の治療薬パイプライン動向（2015年上半期版）...市場調査レポートについてご紹介

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Prader-Willi Syndrome (PWS) Overview 6
Therapeutics Development 7
Pipeline Products for Prader-Willi Syndrome (PWS) – Overview 7
Pipeline Products for Prader-Willi Syndrome (PWS) – Comparative Analysis 8
Prader-Willi Syndrome (PWS) – Therapeutics under Development by Companies 9
Prader-Willi Syndrome (PWS) – Pipeline Products Glance 10
Late Stage Products 10
Clinical Stage Products 11
Early Stage Products 12
Prader-Willi Syndrome (PWS) – Products under Development by Companies 13
Prader-Willi Syndrome (PWS) – Companies Involved in Therapeutics Development 14
Chong Kun Dang Pharmaceutical Corp. 14
Essentialis, Inc. 15
Ferring International Center S.A. 16
LG Life Sciences, Ltd. 17
P2D Bioscience 18
Pfizer Inc. 19
Rhythm Pharmaceuticals 20
Prader-Willi Syndrome (PWS) – Therapeutics Assessment 21
Assessment by Monotherapy Products 21
Assessment by Target 22
Assessment by Mechanism of Action 24
Assessment by Route of Administration 26
Assessment by Molecule Type 28
Drug Profiles 30
beloranib – Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
betahistine hydrochloride – Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
diazoxide choline CR – Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
FE-992097 – Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
NOX-B11 – Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
setmelanotide – Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
somatropin SR – Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
Prader-Willi Syndrome (PWS) – Recent Pipeline Updates 42
Prader-Willi Syndrome (PWS) – Product Development Milestones 47
Featured News & Press Releases 47
Nov 14, 2014: Essentialis To Present Clinical Update At The Annual Research Conference Of The Foundation For Prader-Willi Research 47
Oct 01, 2014: Zafgen Announces Initiation of Phase 3 Trial of Beloranib in Prader-Willi Syndrome 47
Jul 23, 2014: Essentialis Secures Foundation for Prader-Willi Research Grant to Help Advance DCCR in the Treatment of Prader-Willi Syndrome 48
Jul 10, 2014: Zafgen Granted Orphan Drug Designation in the European Union for Beloranib, a First-in-Class MetAP2 Inhibitor for the Treatment of Prader-Willi Syndrome 48
Jun 27, 2014: Essentialis Announces the Dosing of the First Patient in a Clinical Study of DCCR in Prader-Willi Syndrome 49
Jun 17, 2014: Essentialis Announces the Grant of its First Japanese Patent Which Provides Extensive Protection to DCCR in the Treatment of Prader-Willi Syndrome 50
May 28, 2014: Essentialis Obtains Orphan Drug Designation from FDA for DCCR in the Treatment of Prader-Willi Syndrome 50
Jan 15, 2014: Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 51
Appendix 53
Methodology 53
Coverage 53
Secondary Research 53
Primary Research 53
Expert Panel Validation 53
Contact Us 54
Disclaimer 54